Cargando…

Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso

INTRODUCTION: Hepatitis C virus (HCV) infection remains a major public health problem worldwide. In Burkina Faso, nearly 720,000 people are living with HCV, and each year about 900 people die from complications of cirrhosis or hepatocellular carcinoma. This study was planned to determine the HCV ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Yelemkoure, Edwige T., Yonli, Albert T., Sombie, Hermann K., Tao, Issoufou, Zouré, Abdou Azaque, Ouattara, Abdoul Karim, Sorgho, Abel P., Zongo, Arsène W., Zeba, Moctar T.A., Kiendrebeogo, Isabelle T., Bado, Prosper, Kabré, Madeleine K., Zohoncon, Théodora M., Djigma, Florencia W., Obiri-Yeboah, Dorcas, Simpore, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501785/
https://www.ncbi.nlm.nih.gov/pubmed/34583364
http://dx.doi.org/10.1159/000519848
_version_ 1784795553135067136
author Yelemkoure, Edwige T.
Yonli, Albert T.
Sombie, Hermann K.
Tao, Issoufou
Zouré, Abdou Azaque
Ouattara, Abdoul Karim
Sorgho, Abel P.
Zongo, Arsène W.
Zeba, Moctar T.A.
Kiendrebeogo, Isabelle T.
Bado, Prosper
Kabré, Madeleine K.
Zohoncon, Théodora M.
Djigma, Florencia W.
Obiri-Yeboah, Dorcas
Simpore, Jacques
author_facet Yelemkoure, Edwige T.
Yonli, Albert T.
Sombie, Hermann K.
Tao, Issoufou
Zouré, Abdou Azaque
Ouattara, Abdoul Karim
Sorgho, Abel P.
Zongo, Arsène W.
Zeba, Moctar T.A.
Kiendrebeogo, Isabelle T.
Bado, Prosper
Kabré, Madeleine K.
Zohoncon, Théodora M.
Djigma, Florencia W.
Obiri-Yeboah, Dorcas
Simpore, Jacques
author_sort Yelemkoure, Edwige T.
collection PubMed
description INTRODUCTION: Hepatitis C virus (HCV) infection remains a major public health problem worldwide. In Burkina Faso, nearly 720,000 people are living with HCV, and each year about 900 people die from complications of cirrhosis or hepatocellular carcinoma. This study was planned to determine the HCV seroprevalence, characterize circulating genotypes, and monitor HCV viral loads in patients under treatment with antivirals. METHODS: A total of 4,124 individuals and 167 patients in the pre-therapy program were recruited. The “SD Bioline HCV” kit was used for rapid screening of anti-HCV antibodies. Viral load and genotyping were performed in 167 HCV patients on antivirals using the “Iontek HCV Quant” and “Iontek genotyping” kits. RESULTS: Prevalence of HCV was 1.65% (68/4,124), and the median viral load of participants was 5.37 log10/mL (1.32–7.67 log10/mL). Genotype 2 was predominant with a frequency of 86.23% (144/167) and appeared to be more active with higher viral load compared to 13.77% (23/167) for genotype 1 (p < 0.001). After 24 weeks of pan-genotypic direct-acting antivirals, such as sofosbuvir/daclatasvir and sofosbuvir/velpatasvir, the viral loads of all patients became undetectable. CONCLUSION: The responses to antivirals by the circulating genotypes indicate that the results are very satisfactory. Therefore, the prevalence of HCV in the population can be reduced through identification of cases and treatment.
format Online
Article
Text
id pubmed-9501785
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-95017852022-09-24 Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso Yelemkoure, Edwige T. Yonli, Albert T. Sombie, Hermann K. Tao, Issoufou Zouré, Abdou Azaque Ouattara, Abdoul Karim Sorgho, Abel P. Zongo, Arsène W. Zeba, Moctar T.A. Kiendrebeogo, Isabelle T. Bado, Prosper Kabré, Madeleine K. Zohoncon, Théodora M. Djigma, Florencia W. Obiri-Yeboah, Dorcas Simpore, Jacques Intervirology Research Article INTRODUCTION: Hepatitis C virus (HCV) infection remains a major public health problem worldwide. In Burkina Faso, nearly 720,000 people are living with HCV, and each year about 900 people die from complications of cirrhosis or hepatocellular carcinoma. This study was planned to determine the HCV seroprevalence, characterize circulating genotypes, and monitor HCV viral loads in patients under treatment with antivirals. METHODS: A total of 4,124 individuals and 167 patients in the pre-therapy program were recruited. The “SD Bioline HCV” kit was used for rapid screening of anti-HCV antibodies. Viral load and genotyping were performed in 167 HCV patients on antivirals using the “Iontek HCV Quant” and “Iontek genotyping” kits. RESULTS: Prevalence of HCV was 1.65% (68/4,124), and the median viral load of participants was 5.37 log10/mL (1.32–7.67 log10/mL). Genotype 2 was predominant with a frequency of 86.23% (144/167) and appeared to be more active with higher viral load compared to 13.77% (23/167) for genotype 1 (p < 0.001). After 24 weeks of pan-genotypic direct-acting antivirals, such as sofosbuvir/daclatasvir and sofosbuvir/velpatasvir, the viral loads of all patients became undetectable. CONCLUSION: The responses to antivirals by the circulating genotypes indicate that the results are very satisfactory. Therefore, the prevalence of HCV in the population can be reduced through identification of cases and treatment. S. Karger AG 2021-09-28 /pmc/articles/PMC9501785/ /pubmed/34583364 http://dx.doi.org/10.1159/000519848 Text en Copyright © 2021 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
spellingShingle Research Article
Yelemkoure, Edwige T.
Yonli, Albert T.
Sombie, Hermann K.
Tao, Issoufou
Zouré, Abdou Azaque
Ouattara, Abdoul Karim
Sorgho, Abel P.
Zongo, Arsène W.
Zeba, Moctar T.A.
Kiendrebeogo, Isabelle T.
Bado, Prosper
Kabré, Madeleine K.
Zohoncon, Théodora M.
Djigma, Florencia W.
Obiri-Yeboah, Dorcas
Simpore, Jacques
Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso
title Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso
title_full Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso
title_fullStr Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso
title_full_unstemmed Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso
title_short Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso
title_sort seroprevalence, genotyping, and monitoring of hepatitis c viral loads in patients on antivirals in burkina faso
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501785/
https://www.ncbi.nlm.nih.gov/pubmed/34583364
http://dx.doi.org/10.1159/000519848
work_keys_str_mv AT yelemkoureedwiget seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT yonlialbertt seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT sombiehermannk seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT taoissoufou seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT zoureabdouazaque seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT ouattaraabdoulkarim seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT sorghoabelp seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT zongoarsenew seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT zebamoctarta seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT kiendrebeogoisabellet seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT badoprosper seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT kabremadeleinek seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT zohoncontheodoram seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT djigmaflorenciaw seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT obiriyeboahdorcas seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso
AT simporejacques seroprevalencegenotypingandmonitoringofhepatitiscviralloadsinpatientsonantiviralsinburkinafaso